These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 7374415)

  • 61. [What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
    Fortschr Med; 1982 Sep; 100(35):1622-3. PubMed ID: 7173769
    [No Abstract]   [Full Text] [Related]  

  • 62. [D-thyroxin in the therapy of type IIa and IIb hyperlipoproteinemias].
    Hempel RD; Müller G; Burchardt U
    Z Gesamte Inn Med; 1977 Jun; 32(11):suppl 175-6. PubMed ID: 201111
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Clinical study of fenofibrate in hyperlipoproteinemias].
    Ducobu J
    Acta Clin Belg; 1980; 35(3):148-54. PubMed ID: 7456965
    [No Abstract]   [Full Text] [Related]  

  • 64. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia.
    Vecchio TJ; Linden CV; O'Connell MJ; Heilman J
    Arch Intern Med; 1982 Apr; 142(4):721-3. PubMed ID: 7073415
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
    Neuman J; de Neuman MP; Talmasky S; Pesce R; Valero E; Martiarena JL
    J Cardiovasc Surg (Torino); 1973; Spec No():532-7. PubMed ID: 4377715
    [No Abstract]   [Full Text] [Related]  

  • 66. [The use of sorbinicate in the treatment of hyperlipoproteinemia type IIa and IIb].
    Guida L; Grimaldi S; Avella F; Marullo L; Mascio G
    Farmaco Prat; 1981 Jan; 36(1):13-22. PubMed ID: 7227491
    [No Abstract]   [Full Text] [Related]  

  • 67. [Clinico-experimental long-term study on the combined effect of clofibrin and nicotinic acid on abnormal fatty acid patterns in lipid metabolism disorders in the aged].
    Reuter W
    Z Alternsforsch; 1983; 38(1):57-62. PubMed ID: 6405546
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Basic principles of drug therapy of hyperlipoproteinemia].
    Romics L
    Orv Hetil; 1988 Nov; 129(45):2391-9. PubMed ID: 3054710
    [No Abstract]   [Full Text] [Related]  

  • 70. [Clofibrate therapy--current status from a gerontological viewpoint].
    Reuter W
    Z Alternsforsch; 1982; 37(5):341-8. PubMed ID: 7157849
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia.
    Császár A; Karádi I; Köszegi G; Pados G; Németh-Csóka M; Pichler M; Romics L
    Klin Wochenschr; 1990; 68 Suppl 22():96-8. PubMed ID: 2087089
    [No Abstract]   [Full Text] [Related]  

  • 72. Serum lipoprotein pattern after SAMe-treatment.
    Rini GB; Di Fede G; Rotolo G; Rizzo G; Mascellino MR; Affronti M; Delle Vedove G
    Boll Soc Ital Biol Sper; 1987 Oct; 63(10):919-22. PubMed ID: 3447603
    [No Abstract]   [Full Text] [Related]  

  • 73. [Drug therapy of hypertriglyceridemias (author's transl)].
    Gries FA
    MMW Munch Med Wochenschr; 1980 Mar; 122(13):471-3. PubMed ID: 6769019
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pilot study of pirinixil (BR 931) in various forms of hyperlipoproteinemias.
    Najemnik C; Irsigler K; Sirtori CR
    Pharmacol Res Commun; 1981 Sep; 13(8):777-86. PubMed ID: 7027276
    [No Abstract]   [Full Text] [Related]  

  • 75. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate].
    Uglesić A; Ljachnicky N
    Schweiz Rundsch Med Prax; 1988 Jul; 77(27-28):755-61. PubMed ID: 3041534
    [No Abstract]   [Full Text] [Related]  

  • 76. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
    Lageder H
    Wien Klin Wochenschr; 1980 Feb; 92(3):95-101. PubMed ID: 6985560
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
    Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
    [No Abstract]   [Full Text] [Related]  

  • 78. Clofibrate in type II hyperlipoproteinemia.
    Ditzel J; Bang HO
    Acta Med Scand; 1976; 200(1-2):55-58. PubMed ID: 183462
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pre- and post-treatment values of HDL cholesterol and total: HDL cholesterol ratio in hyperlipoproteinaemic subjects.
    Sale JK; Johnstone JH
    Ann Clin Biochem; 1981 Mar; 18 (Pt 2)():71-5. PubMed ID: 7259072
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Use of miskleron in ischemic heart disease with differing types of hyperlipoproteinemias].
    Krivoruchenko IV; Nikul'cheva NG
    Kardiologiia; 1976 Jul; 16(7):71-5. PubMed ID: 185448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.